Prevalence of high-risk aortic arch atherosclerosis features on computed tomography angiography in embolic stroke of undetermined source.


Journal

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 22 03 2023
revised: 17 07 2023
accepted: 14 09 2023
medline: 24 11 2023
pubmed: 10 10 2023
entrez: 9 10 2023
Statut: ppublish

Résumé

Embolic stroke of undetermined source (ESUS) comprises a heterogenous group. There is a need to further identify etiologies within this group to guide management strategies. We examined the prevalence of aortic arch atherosclerosis (AAA) on CT angiography (CTA) in patients with embolic stroke of undetermined source (ESUS) to characterize high-risk plaque features. All patients from two prospective multicenter acute ischemic stroke studies (INTERRSeCT and PRove-IT) were included if the CTA adequately imaged the proximal aortic arch and the stroke etiology was recorded. Three readers blinded to stroke etiology analyzed the following AAA plaque features on baseline CTA at the time of stroke: 1) thickness in millimetres (mm); 2) morphology (none, smooth, ulcerated, or protruding); 3) location within the aortic arch (proximal, transverse, or distal); and 4) calcification (none, single small, multiple small, single large, or diffuse extensive). We included 1063 patients, of which 293 (27.6%) had ESUS (mean age 67.5 years; 46.4% men; median NIHSS 12; 80.6% large vessel occlusion). Mean AAA thickness was significantly larger in ESUS patients (3.8 mm) compared to non-ESUS patients (3.0 mm; p<0.0001) and to a subgroup of patients with large artery atherosclerosis (2.9 mm; p=0.003). ESUS patients had a significantly higher proportion of ulcerated or protruding plaques (17.4% vs 10.3%; risk ratio 1.7, 95% C.I. 1.2-2.4, p=0.002). The location of AAA in the ESUS group was the ascending aorta in 37.9%, transverse arch in 42.3%, and descending aorta in 84.6%. Although AAA was mostly located in the distal aortic arch, ulcerated or protruding plaques were least common in the distal arch (p=0.002). There was no difference between ESUS and non-ESUS patients in plaque location (p=0.23) or calcification grade (p=0.092). ESUS patients in our study had thicker AAA and a higher prevalence of ulcerated or protruding plaques located more proximally within the aortic arch. High-risk plaque features may suggest a causal role of AAA in the ESUS population with visible intracranial occlusions.

Identifiants

pubmed: 37813086
pii: S1052-3057(23)00397-X
doi: 10.1016/j.jstrokecerebrovasdis.2023.107374
pii:
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107374

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors confirm there are no conflicts of interest. No part of this manuscript was created using artificial intelligence. The data in this manuscript has not been published in any other journal

Auteurs

Matthew Boyko (M)

Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Canada. Electronic address: matthew.boyko@interiorhealth.ca.

Surbhi Chaturvedi (S)

Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Canada.

Benjamin Beland (B)

Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Canada.

Mohamed Najm (M)

Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Canada.

Andrew M Demchuk (AM)

Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Canada.

Bijoy K Menon (BK)

Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Canada.

Mohammed Almekhlafi (M)

Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH